151. Folate receptor-mediated delivery of mitoxantrone-loaded solid lipid nanoparticles to breast cancer cells
- Author
-
Andreia Granja, Cláudia Nunes, Célia T. Sousa, and Salette Reis
- Subjects
Pharmacology ,Drug Carriers ,Cell Survival ,Antineoplastic Agents ,Breast Neoplasms ,General Medicine ,Polyethylene Glycols ,Drug Delivery Systems ,Folic Acid ,Cell Line, Tumor ,Liposomes ,Humans ,Nanoparticles ,Female ,Mitoxantrone - Abstract
The standard breast cancer therapy still faces major challenges due to non-specific tumor distribution and occurrence of dose-limiting adverse side-effects. Nanomedicine constitutes an appealing approach to improve the therapeutic index of different anti-cancer drugs. Given their biocompatibility, low-cost manufacture and easy surface modification, lipid nanoparticles, such as solid lipid nanoparticles (SLN), have a great potential for drug delivery in cancer therapy. In this work, SLN entrapping the antineoplastic drug Mitoxantrone (Mito) were developed and functionalized with Disteroylphosphatidylethanolamine-poly(ethylene glycol)-folic acid (DSPE-PEG-FA) ligand to improve blood circulation and tumor selectivity and limit the drug systemic side-effects. Nanoparticles presented adequate size and size distribution for intravenous injection and were stable for at least 6 months. Additionally, their hemocompatibility was demonstrated. Moreover, functionalized nanoparticles were able to improve the anti-cancer effect of the free drug, as assessed by the values of IC
- Published
- 2022
- Full Text
- View/download PDF